JP2000509394A5 - - Google Patents

Download PDF

Info

Publication number
JP2000509394A5
JP2000509394A5 JP1997539221A JP53922197A JP2000509394A5 JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5 JP 1997539221 A JP1997539221 A JP 1997539221A JP 53922197 A JP53922197 A JP 53922197A JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997539221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/007335 external-priority patent/WO1997040854A2/en
Publication of JP2000509394A publication Critical patent/JP2000509394A/ja
Publication of JP2000509394A5 publication Critical patent/JP2000509394A5/ja
Ceased legal-status Critical Current

Links

JP9539221A 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体 Ceased JP2000509394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028,609 1996-10-23
US60/016,347 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
JP2000509394A JP2000509394A (ja) 2000-07-25
JP2000509394A5 true JP2000509394A5 (enExample) 2004-12-09

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9539221A Ceased JP2000509394A (ja) 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体

Country Status (5)

Country Link
EP (1) EP0966303A2 (enExample)
JP (1) JP2000509394A (enExample)
AU (1) AU729643B2 (enExample)
CA (1) CA2252706A1 (enExample)
WO (1) WO1997040854A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973886B1 (en) * 1997-01-24 2005-03-23 AVI BioPharm, Inc. Method and conjugate for treating helicobacter pylori infections
US6455495B1 (en) * 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP2269654A3 (en) * 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
EP3020804A1 (en) 2000-07-06 2016-05-18 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method
EP2364734B1 (en) 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ, インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
WO2006085973A2 (en) 2004-07-02 2006-08-17 Avi Biopharma, Inc. Antisense antibacterial method and compound
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
WO2006094193A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1915161B1 (en) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2009225590B2 (en) 2008-03-20 2013-05-02 Stephen H. Bartelmez Enhancing vessel lesion homing and repair potential of stem cells
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2011012875A (es) 2009-06-05 2012-02-28 13Therapeutics Inc Peptidos inmunoreguladores y metodos de uso.
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
JP2013530154A (ja) 2010-05-28 2013-07-25 サレプタ セラピューティクス, インコーポレイテッド 修飾されたサブユニット間結合および/または末端基を有するオリゴヌクレオチドアナログ
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
BR112014011875B1 (pt) 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
EP3377067A4 (en) * 2015-10-07 2019-07-31 Cormedix Inc. SKIN-PENETRATING FORMULATION OF TAUROLIDINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000515705A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000500184A5 (enExample)
JP2000501569A5 (enExample)